/ /

  • linkedin
  • Increase Font
  • Sharebar

    New ocular allergy drug’s MOA targets inflammation


    Some future considerations

    The evidence from the study showed that the drug works acutely in patients with allergic conjunctivitis. However, a question remains about when the therapy can be used prophylactically in patients prone to allergic conjunctivitis.

    Recent: What punctal plug delivery of dexamethasone means for allergic conjunctivitis

    Dr. Clark pointed out that prophylactic use is preferred for this patient population, but no decision has been made about a treatment program for clinical practice.

    Anne Marie Salapatek, PhD, president and chief scientific officer, Inflamax Research, a contract research organization that conducted the study, commented that the data seem to show that patients could safely use the drug continuously during seasons when they are particularly susceptible to allergic events. Dr. Salapatek added that formal dosing schedules still remain to be investigated.

    Related: Getting to the root cause of ocular allergy

    Some anti-histamine-refractory patients are treated chronically with topical corticosteroids, which could lead to complications of increased intraocular pressure and steroid-induced glaucoma.

    “The potential for this drug to be used over the long term is very exciting when considering the possibility of eliminating some side effects associated with corticosteroids,” Dr. Salapatek said. “NS2 might fill an unmet need for these patients.”

    Related: What Thomas Edison and goldenrod teach us about allergy

    Aldeyra Therapeutics plans to issue guidance on the clinical development plan of topical ocular NS2 during the second quarter of 2016.

    Other potential indications

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results